In this episode of Community Corner, Christopher H. Lieu, MD, professor of medicine at the University of Colorado Cancer ...

MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...

Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...

Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...

The pivotal MajesTEC-3 trial led to FDA approval of teclistamab-daratumumab for relapsed/refractory multiple myeloma after at ...

Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines ...

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

NCCN now recognizes image-only, mammogram-derived AI as a primary risk tool, shifting risk stratification from ...